Table I.
Comparison of basic data between the two groups of patients [n (%)].
| Groups | ||||
|---|---|---|---|---|
| items | Combined therapy (n=50) | Oxaliplatin (n=51) | χ2 | P-value |
| Sex | ||||
| Male | 28 (56.00) | 32 (62.75) | 0.476 | 0.490 |
| Female | 22 (44.00) | 19 (37.25) | ||
| Age (years) | ||||
| >50 | 23 (46.00) | 28 (54.90) | 0.800 | 0.371 |
| ≤50 | 27 (54.00) | 23 (45.10) | ||
| History of disease | ||||
| Hepatitis B | 16 (32.00) | 20 (39.22) | 0.705 | 0.703 |
| Hepatitis C | 25 (50.00) | 24 (47.06) | ||
| Others | 9 (18.00) | 7 (13.73) | ||
| TNM stage | 0.240 | 0.624 | ||
| I–II | 31 (62.00) | 34 (66.67) | ||
| III–IV | 19 (38.00) | 17 (33.33) | ||
| Diameter of tumor | 0.170 | 0.680 | ||
| ≥2 cm | 39 (78.00) | 38 (74.51) | ||
| <2 cm | 11 (22.00) | 13 (25.49) | ||
| Treatment range | 1.208 | 0.227 | ||
| Sub-segment | 20 (40.00) | 13 (25.49) | ||
| Segment | 14 (28.00) | 19 (37.25) | ||
| Lobe | 13 (26.00) | 15 (29.41) | ||
| Whole liver | 3 (6.00) | 4 (7.84) | ||
| No. of tumors treated | 0.286 | 0.775 | ||
| 1 | 19 (38.00) | 17 (33.33) | ||
| 2 | 11 (22.00) | 13 (25.49) | ||
| 3 | 4 (8.00) | 6 (11.76) | ||
| 4 | 5 (10.00) | 3 (5.88) | ||
| ≥5 | 11 (22.00) | 12 (23.53) | ||